.Charles Baum, M.D., Ph.D., that managed Mirati Therapies' $ 5.8 billion sale to Bristol Myers Squibb last year, is actually taking the helm of younger biotech Terremoto Biosciences.Baum's "substantial experience in medicine development, and also established record earlier high-impact medicines, will contribute," outbound chief executive officer Peter Thompson, M.D., said in a July 25 launch. Thompson will definitely preserve his chair as board chairperson..Baum, a trained physician-scientist, was the founder, president and also chief executive officer of oncology-focused Mirati. Before that, he aided cultivate cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will certainly serve as chief executive officer at Terremoto, a firm establishing tiny molecules to target disease-causing proteins-- like those found in malignant lump tissues-- using covalent connects. Existing treatments that utilize covalent bonds predominantly target the amino acid cysteine. However, of the 20 amino acids that comprise healthy proteins, cysteine is the minimum usual. Terremoto is actually as an alternative targeting among the crucial amino acids, lysine, which is located in almost all proteins.Through targeting amino acid lysine and also other amino acids, Terremoto expects to handle earlier undruggable conditions and also develop first-in-class medications..The biotech, based in South San Francisco, brought up $75 thousand in series A backing in 2022. A little more than a year eventually, the biotech more than increased that variety in a $175 thousand set B.